The Case of The Wild Kinase

Immunotherapy advances in triple-negative breast cancer drive personalized treatments with immune checkpoint inhibitors, aiding subtype identification and new combination therapy developments.

David A. Russler-Germain, MD, PhD, discusses his path in oncology and the many advancements shaping lymphoma treatment today.

For Colorectal Cancer Awareness Month, Scott Kopetz, MD, PhD, FACP, discussed the BREAKWATER trial in metastatic BRAF V600E-mutated colorectal cancer.

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard care in this patient population.

Waystar's AI-powered AltitudeAI automates claim appeals, aiming to recover billions in denied payments and reduce healthcare administrative waste.